Kedar Upad — CEO Promise Tracker & Credibility Score

Promise Delivery Record

📊

Scorecard building

ConCallIQ tracks whether management promises made on earnings calls are delivered. Data for Kedar Upad is being built as historical quarters are processed. Check back next quarter.

Notable Quotes

We have four molecules in the zone of $200 million annualized revenues and adalimumab was one of that.

Kedar Upad · Biocon Q3 FY26

Earnings Appearances

Biocon · Q3 FY26

Read earnings analysis →